Related Experiment Video

Updated: May 22, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Targeted therapy for advanced urothelial cancer of the bladder: where do we stand?

Zhaowei Zhu1, Zhoujun Shen, Chen Xu

  • 1Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Anti-Cancer Agents in Medicinal Chemistry
|May 16, 2012
PubMed

Insights

Novel targeted therapies show promise for advanced urothelial bladder cancer, but results vary. Bevacizumab and trastuzumab offer benefits, while other agents need further investigation for improved patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Chemotherapy remains standard for advanced urothelial bladder cancer, offering survival benefits but causing significant side effects.
  • Targeted therapies represent a promising new direction for improving patient outcomes by targeting specific molecular pathways.

Purpose of the Study:

  • To systematically review clinical data on novel targeted agents for advanced urothelial bladder cancer.
  • To evaluate the efficacy of agents like bevacizumab, aflibercept, sunitinib, sorafenib, gefitinib, lapatinib, trastuzumab, pazopanib, cetuximab, and everolimus.

Main Methods:

  • Systematic review of 10 phase II clinical trials.
  • Analysis of clinical data for various targeted agents in urothelial bladder cancer treatment.

Main Results:

  • Bevacizumab and trastuzumab demonstrated promising results in advanced urothelial bladder cancer.
  • Other targeted agents did not achieve the same clinical benefit as observed in other epithelial cancers.
  • The efficacy of targeted agents varies significantly in this patient population.

Conclusions:

  • Targeted therapy offers a promising avenue for advanced urothelial bladder cancer, though efficacy differs among agents.
  • Combination, sequential, adjuvant, and neoadjuvant targeted therapy approaches may offer the best outcomes.
  • Further research is needed to optimize targeted therapy strategies for urothelial bladder cancer.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.